PT  - JOURNAL ARTICLE
AU  - Md. Asad Ullah
AU  - Bishajit Sarkar
AU  - Yusha Araf
AU  - Md. Nazmul Islam Prottoy
AU  - Ananna Saha
AU  - Tanjila Jahan
AU  - Aisha Siddiqua Boby
AU  - Md. Shariful Islam
TI  - Integrated Bioinformatic Approach to Identify Potential Biomarkers against Idiopathic Pulmonary Fibrosis
AID  - 10.1101/2019.12.12.19014746
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 2019.12.12.19014746
4099  - http://medrxiv.org/content/early/2019/12/15/2019.12.12.19014746.short
4100  - http://medrxiv.org/content/early/2019/12/15/2019.12.12.19014746.full
AB  - Idiopathic Pulmonary Fibrosis (IPF) is a chronic and progressive lung disease that leads to gradual decline in lung function. The molecular mechanism and risk factors of this disease are still obscure. Poorly understood etiology of this disease is the major obstacle in the identification of potential biomarkers and drug targets. In this study, microarray gene expression data of normal and IPF patient has been utilized for the statistical analysis of differentially expressed genes (DEGs) with a view to identifying potential molecular signatures using network-based system. Then their functional enrichment analysis revealed their predominant involvement in transcription, protein acetylation, extracellular matrix organization, apoptic process, inflammatory response etc. Protein-Protein Interaction (PPI) network revealed (UBC, PTEN, SOS1, PTK2, FGFR1, YAP1, FOXO1, RACK1, BMP4 and CD44) as hub proteins in IPF. Subsequent regulatory network analysis suggested (E2F1, STAT3, PPARG, MEF2A, FOXC1, GATA3, YY1, GATA2, NFKB1, and FOXL1) as the best regulatory transcriptional signatures and (hsa-mir-155-5p, hsa-mir-16-5p, hsa-mir-17-5p, hsa-mir-19a-3p, hsa-mir-192-5p, hsa-mir-92a-3p, hsa-mir-26b-5p, hsa-mir-335-5p, hsa-mir-124-3p, and hsa-let-7b-5p) as the best post-transcriptional signatures. This study represents proteome and RNA signatures of IPF which might be useful to uphold the present efforts in the discovery of potential biomarkers and treatments of this disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAuthors received no specific funding from any external source.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAuthors made all data generated during experiment and analysis available in the manuscript.